secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041889
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q2 2023 net loss $1.4M; cash $15.7M; 6-month net income $4.7M on warrant gain
--------------------------------------------------------------------------------

- Cash and cash equivalents of $15.7M as of June 30, 2023, up from $5.3M at Dec 31, 2022.
- Net loss for Q2 2023 was $1.4M ($0.25 per share) vs $1.8M ($4.16 per share) in Q2 2022.
- Net income for 6 months ended June 30, 2023 was $4.7M ($1.61 basic EPS) vs net loss of $8.5M in prior period, driven by $8.2M warrant liability gain.
- Net cash used for operating activities for 6 months ended June 30, 2023 was $3.6M, down from $8.5M year-over-year.
- Management believes current cash sufficient to fund operations through June 2024; decreased clinical study expenses contributed to lower losses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/0000950170-23-041889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/revb-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer